Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on April 27, 2020. The filing discloses the entry into a material definitive agreement involving a loan under the Paycheck Protection Program (PPP) and an amendment to an existing financing agreement.
Key Financial Metrics
- Debt: The Company received a PPP Loan with a principal amount of $6,477,094.
- Interest Rate: The loan bears interest at a fixed rate of 1.00% per annum.
- Maturity: The loan matures on the two-year anniversary of the funding date.
- Repayment Terms: Monthly principal and interest payments commence after the six-month anniversary of the funding date, subject to forgiveness.
- Collateral: No collateral or guarantees were provided, and no facility charge was paid.
- Liquidity: The filing does not provide specific cash flow, revenue, or liquidity metrics beyond the loan receipt.
Material Changes
The primary material change is the incurrence of the $6,477,094 PPP Loan from Bank of America, NA. Concurrently, the Company amended its Financing Agreement dated April 24, 2019, to permit the incurrence of this loan and to add affirmative covenants related to the PPP Loan.
Guidance, Outlook, and Risks
Loan Forgiveness: The Company may apply for forgiveness of all or a portion of the loan between 60 and 90 days after the funding date. Forgiveness is based on documented payroll costs, covered rent, and utilities during an eight-week period. The Company currently believes it will meet the conditions for forgiveness but cannot assure it will be forgiven in whole or in part.
Risks and Contingencies: The filing highlights significant risks, including:
- Uncertainty regarding the ability to comply with PPP Loan covenants and forgiveness conditions.
- Impact of the COVID-19 pandemic on operations and sales.
- Commercialization challenges for products IMVEXXY, ANNOVERA, and BIJUVA.
- Need for additional financing to support development and commercialization.
- Regulatory risks, including FDA approval for BIJUVA and intellectual property disputes.
Investor Verification Checklist
- Verify the final determination of loan forgiveness by the SBA and Bank of America.
- Review the full text of the amended Financing Agreement for specific affirmative covenants.
- Monitor the Company's ability to maintain full-time headcount and salary levels to maximize forgiveness eligibility.
- Assess the impact of the COVID-19 pandemic on the commercialization of IMVEXXY, ANNOVERA, and BIJUVA.
- Track the status of FDA approvals and intellectual property litigation regarding the Company's drug candidates.